Skip to content

Evaluation of the Intranasal Fentanyl Protocol in Pediatric Surgical Emergencies at Strasbourg University Hospital

Evaluation of the Intranasal Fentanyl Protocol in Pediatric Surgical Emergencies at Strasbourg University Hospital

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06832046
Acronym
TraumaDol
Enrollment
500
Registered
2025-02-18
Start date
2024-10-28
Completion date
2026-04-28
Last updated
2025-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Musculoskeletal Pain

Keywords

Pain Syndrome, Intranasal Fentanyl, pediatric, Pediatric surgical emergency

Brief summary

Emergency trauma departments receive thousands of patients each year whose main symptom is pain. In recent years, intranasal fentanyl (FIN) has entered the therapeutic arsenal to treat pain in the emergency department. Various studies have validated its effectiveness for musculoskeletal pain as well as its tolerance and safety of use. Since then, new protocols have been implemented including this treatment. In This study, the investigators propose to retrospectively study the quality of prescription of intranasal fentanyl in the treatment of pain in the emergency department and the quality of monitoring of this treatment in current practice.

Interventions

None listed

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Years to 17 Years

Inclusion criteria

* Child \< 18 years old * Child treated in the pediatric emergency department of Strasbourg University Hospital * Child who has benefited from intranasal fentanyl between 08/01/2022 and 09/31/2024. * Child (and/or his/her parental authority) who has not expressed, after information, his/her (their) opposition to the reuse of his/her health data for the purposes of this research.

Exclusion criteria

* Refusal of the child (and/or his/her parent) to participate in the study * Patient's medical file not incomplete * Child not domiciled in France.

Design outcomes

Primary

MeasureTime frameDescription
The judgment criterion is composite in order to retrospectively evaluate the relevance of the prescription, administration and monitoring of the intranasal fentanyl (FIN) protocol.Up to 2 yearsThe judgment criterion includes, 1) the prescription and 2) the administration and monitoring. 1\) Concerning the prescription: * Compliance with the contraindications of intranasal fentanyl (weight less than 10kg and/or age less than 1 year). * Compliance with the medical indication according to the protocol (pathologies and/or procedures performed and/or initial assessment of pain). * Compliance with the prescription terms (indication of the dead space, unit, route of administration and dose).
The judgment criterion is composite in order to retrospectively evaluate the relevance of the prescription, administration and monitoring of the intranasal fentanyl (FIN) protocol.The judgment criterion includes,Up to 2 yearsThe judgment criterion includes, 1) the prescription and 2) the administration and monitoring. 2\) Concerning the administration and monitoring: * Compliance with the double nursing check, product administration schedule and identification of the caregiver. * Nursing monitoring in accordance with the protocol, i.e. taking hemodynamic and respiratory constants (Sat02, FR, FC and TA) before taking fentanyl, at 10-15 minutes, at 30 minutes and at 1 hour.

Countries

France

Contacts

Primary ContactDimitar TCHOMAKOV, MD
Dimitar.tchomakov@chru-strasbourg.fr33 3 88 12 81 18

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026